Original analysis · CMS Federal Upper Limits file · March 2016 to October 2026

For 59% of generic products, the federal payment ceiling is the pharmacy survey price

Federal rule sets the Medicaid ceiling on a generic at 175 percent of the manufacturer price, with one exception: where that would fall below what pharmacies actually pay, the ceiling is raised to the pharmacy survey cost. In October 2026, 917 of 1,543 product groups in CMS's file carry the flag for the exception. The ceiling is a maximum for Medicaid reimbursement, not a price a patient pays.

59.4%of 1,543 product groups flagged in October 2026
135 of 142flagged NDCs in our library whose limit equals the NADAC within half a percent
192 of 192unflagged limits equal to exactly 1.75 times the weighted AMP

Every month since March 2016

The share of rows in each monthly file whose multiplier flag is Y. It ran from 32.6% (November 2024) to 60.3% (June 2025) and stands at 57.5% in October 2026. We have not explained the low point.

0%25%50%75%100%2018202020222024202657.5%low 32.6%Share of federal upper limit rows with the multiplier flag set to Y, by month

Swipe to read across

Source: CMS ACA Federal Upper Limits file, 128 monthly periods, counted by OmniRx. Each point is a recomputable derived fact (input file SHA-256 and script recorded).
OctoberRowsFlaggedShareProduct groups flagged
October 202118,2969,23550.5%749 of 1,342
October 202218,07610,51758.2%834 of 1,318
October 202318,7037,99142.7%643 of 1,336
October 202420,06310,80853.9%857 of 1,474
October 202520,19711,58157.3%923 of 1,518
October 202619,47611,19157.5%917 of 1,543

The rule, in plain terms

42 CFR 447.514(b)(1). The ceiling is a dispensing fee set by the state plus 175 percent of the weighted average of the most recently reported monthly manufacturer prices (AMP). (b)(2), the exception. If that amount is lower than the average pharmacy acquisition cost found by the most current national survey, CMS instead uses the percentage of AMP that equals the survey cost. (a)(1). The list covers drugs FDA rates as pharmaceutically and therapeutically equivalent in at least three products, which is why every group in this file is already a multiple-source generic. (c)(1). The AMP of a terminated NDC stops counting from the first day of the month after the termination date the manufacturer reported; see the termination calendar. We read the rule text on eCFR on 2026-11-11.

Worked examples, October 2026

Flagged limits that equal the pharmacy cost, where 175 percent of the weighted AMP would have been far lower. Prices are per unit.

DrugFormWeighted AMP1.75 times AMPFederal limitNADAC
glyburide 5 mgtablet$0.016$0.028$0.068$0.068
mesalamine 0.375gcap er 24h$0.115$0.201$0.484$0.484
ketorolac tromethamine 10mgtablet$0.041$0.073$0.170$0.170
morphine sulfate 15mgtablet$0.056$0.098$0.223$0.223
felodipine 10mgtablet, extended release$0.035$0.062$0.130$0.130
calcitriol 0.25mcgcapsule$0.041$0.072$0.151$0.151
What this does and does not show. It shows which rule produced each ceiling. It does not show that any government payer overpays: a ceiling is a maximum, and states pay by their own formulas. A federal limit is not a price a patient pays.

Questions

What is a federal upper limit?

For a generic drug that FDA rates as equivalent in at least three products, CMS publishes a ceiling on what state Medicaid programs may pay in aggregate for the ingredient. It is a Medicaid reimbursement ceiling, not a price a patient pays.

How is the limit normally set?

Federal rule 42 CFR 447.514(b)(1) sets it at 175 percent of the weighted average of the most recently reported monthly average manufacturer prices (AMP), plus a state dispensing fee. In the file, all 192 current limits that are not flagged equal exactly 1.75 times the weighted AMP.

When is it not 175 percent of AMP?

Paragraph (b)(2) is an exception: if 175 percent of AMP is lower than the average pharmacy acquisition cost found by the most recent national survey, CMS uses the percentage of AMP that equals that survey cost. In the file those rows carry a multiplier-greater-than-175-percent flag. Of the 142 flagged NDCs in our library with a current NADAC price, 135 have a limit equal to the NADAC to within half a percent.

Does this show the government overpays?

No. It shows which rule produced each ceiling. A ceiling is a maximum, and pharmacies are paid by each state's own formula. We make no claim about what any state pays.

What are the limits of this analysis?

The equality with NADAC was measured only on the NDCs already in the OmniRx library, not the whole file. We read the rule text, not CMS's own description of the flag column. The sharp drops in the series, lowest in November 2024 with an earlier local dip in late 2023, are real in the file and we have not explained them.

Sources and recompute. CMS ACA Federal Upper Limits file (data.medicaid.gov catalog statement: usa.gov government works), CMS NADAC, and 42 CFR 447.514 (eCFR). The monthly series is 128 derived facts and the equality figures one more, each carrying the SHA-256 of its input and the script that computes it, served at the findings file; method and edition roots are on the provenance and editions pages. Free to cite with attribution. Not medical, legal or financial advice. Licence the data.